Sarepta Therapeutics (SRPT) Amortizatization of Intangibles (2014 - 2026)
Sarepta Therapeutics (SRPT) recorded quarterly Amortizatization of Intangibles of -$530000.0 in Q1 2026, down 39.47% quarter-over-quarter from -$380000.0 in Q4 2025, and up 72.28% on a YoY basis from -$307638.1 in Q1 2025.
Sarepta Therapeutics (SRPT) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
Sarepta Therapeutics' Amortizatization of Intangibles history runs 10 years deep, the most recent figure standing at -$530000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 72.28% year-over-year to -$530000.0; the TTM figure through Mar 2026 stood at -$3.9 million (up 86.88% YoY), while the FY2025 annual figure was -$5.3 million, up 86.86% from the prior year.
- Amortizatization of Intangibles was -$530000.0 for Q1 2026 at Sarepta Therapeutics, down from -$380000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of -$50000.0 in Q1 2022 to a low of -$13.3 million in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged -$6.1 million across 5 years, with a median of -$6.1 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles tumbled 17202.0% in 2023, then jumped 94.41% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at -$6.1 million in 2022, then slumped by 117.33% to -$13.3 million in 2023, then jumped by 48.96% to -$6.8 million in 2024, then surged by 94.41% to -$380000.0 in 2025, then slumped by 39.47% to -$530000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$530000.0 (Q1 2026), -$380000.0 (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Sarepta Therapeutics | 1.61 Bn | 923.39 Mn | 291.52 Mn | -530,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -530,000.00 |
| Mar 31, 2026 | -530,000.00 |
| Dec 31, 2025 | -380,000.00 |
| Dec 31, 2025 | -380,000.00 |
| Sep 30, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -1.87 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | -6.80 Mn |
| Dec 31, 2024 | -6.80 Mn |
| Sep 30, 2024 | -10.62 Mn |
| Sep 30, 2024 | -10.62 Mn |
| Jun 30, 2024 | -10.46 Mn |
| Jun 30, 2024 | -10.46 Mn |
| Mar 31, 2024 | -12.40 Mn |
| Mar 31, 2024 | -12.40 Mn |
| Dec 31, 2023 | -13.33 Mn |
| Dec 31, 2023 | -13.33 Mn |